Skip to main content
SpringerLink
Log in

Therapeutic Interchange as a Cost-Containment Measure

  • Correspondence
  • Published:
PharmacoEconomics Aims and scope Submit manuscript

Conclusion

Based on personal experience and published findings of other researchers, TI is an effective cost-containment measure. With the changing healthcare environment, more congressional and public involvement in the US, and introduction of very expensive biotechnology drugs, the emphasis of TI may shift from cost containment to cost effectiveness. More work is needed in this area.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  • Achusim LE. Antibiotic use following implementation of a therapeutic interchange program. Pharmacology and Therapeutics 17: 775–777, 780–781, 786–787, 797–798, 1992

    Google Scholar 

  • ASHP Government Affairs Division. Summary of 1990 Medicaid drug rebate legislation. American Journal of Hospital Pharmacy 48: 114–117, 1991

    Google Scholar 

  • Bassand JP, Cassagnes J, Machecourt J, Lusson JR, Anguenot T, et al. Comparative effects of APSAC and rt-PA on infarct size and left ventricular function in acute myocardial infarction: a multicenter randomized study. Circulation 84: 1107–1117, 1991

    Article  PubMed  CAS  Google Scholar 

  • Berkowitz HS. Formulary designation of cimetidine as the primary intravenous histamine H2-receptor antagonist. American journal of Hospital Pharmacy 49: 134–135, 1992

    PubMed  CAS  Google Scholar 

  • Brown GR, Clarke AM. Therapeutic interchange of cefazolin with metronidazole for cefoxitin. American Journal of Hospital Pharmacy 49: 1946–1950, 1992

    PubMed  CAS  Google Scholar 

  • Crawford SY. ASHP national survey of hospital-based pharmaceutical services-1990. American Journal of Hospital Pharmacy 47: 2665–2695, 1990

    PubMed  CAS  Google Scholar 

  • Drummond MF, Stoddart GL, Torrance GW. Methods for the economic evaluation of health care programmes. Oxford Medical Publications, Oxford, 1987

    Google Scholar 

  • Ensor PA. Projecting future drug expenditures-1992. American Journal of Hospital Pharmacy 49: 140–145, 1992

    PubMed  CAS  Google Scholar 

  • Esrig BC, Fulton RL. Sepsis, resuscitated hemorrhagic shock and ‘shock lung’: an experimental correlation. Annals of Surgery 182: 218–227, 1975

    Article  PubMed  CAS  Google Scholar 

  • Fletcher CV, Metzler D, Borchardt-Phelps P, Rodman JH. Patterns of antibiotic use and expenditures during 7 years at a university hospital. Pharmacotherapy 10: 199–204, 1990

    PubMed  CAS  Google Scholar 

  • Fink JL. Hospital formulary system/drug product selection: similar or not? Hospital Pharmacy 18: 590, 595-596, 1983

    PubMed  Google Scholar 

  • Freund DA, Dittus RS. Principles of pharmacoeconomic analysis of drug therapy. PharmacoEconomics 1: 20–31, 1992

    Article  PubMed  CAS  Google Scholar 

  • Green ER, Chrymko MM, Rozek SL, Kitrenos JG. Clinical considerations and costs associated with formulary conversion from tobramycin to gentamicin. American Journal of Hospital Pharmacy 46: 714–719, 1989

    PubMed  CAS  Google Scholar 

  • Guastella C. Cost savings realized from interchanging ceftizoxime for cefoxitin. American Journal of Hospital Pharmacy 45: 2376–2377, 1988

    PubMed  CAS  Google Scholar 

  • Hess DA, Mahoney CD, Johnson PN, Corrao WM, Fisher AE. Integration of clinical and administrative strategies to reduce expenditures for antimicrobial agents. American Journal of Hospital Pharmacy 47: 585–591, 1990

    PubMed  CAS  Google Scholar 

  • Holzman MS. Antimicrobial formulary management: a consultant’s perspective. Pharmacotherapy 11 (Suppl. 1, part 2): S14–S18, 1991

    Google Scholar 

  • Jordan NS, Kelly N. Hospital charges and reimbursement for alteplase and streptokinase. American Journal of Hospital Pharmacy 47: 296, 1990

    PubMed  CAS  Google Scholar 

  • Kohler JP, Rice CL, Zarins CK, Cammack BF, Moss GS. Does reduced colloid oncotic pressure increase pulmonary dysfunction in sepsis? Critical Care Medicine 9: 90–93, 1981

    Article  PubMed  CAS  Google Scholar 

  • Kunin CM, Tupasi T, Craig WA. Use of antibiotics: a brief exposition of the problem and some tentative solutions. Annals of Internal Medicine 79: 555–560, 1973

    PubMed  CAS  Google Scholar 

  • Lamy PP, Palumbo FB. Therapeutic substitution: putting the patient first. Pharmacy Times 56: 41–45, Feb 1990

    Google Scholar 

  • Lincoln LL, Dudley MN. Potential effect of oral antimicrobial therapy on nurse staffing requirements. American Journal of Hospital Pharmacy 47: 386–388, 1990

    PubMed  CAS  Google Scholar 

  • Matanin D, Ament P, Cutrell D. Therapeutic interchange: a community hospital’s approach. Pharmacology and Therapeutics 17: 1123–1124, 1129-1130, 1133, 1992

    Google Scholar 

  • McEvoy GK. AHFS drug information 92. American Society of Hospital Pharmacists, Bethesda, Maryland, 1992

    Google Scholar 

  • Moss GS, Lowe RJ, Jilek J, Levine HD. Colloid or crystalloid in the resuscitation of hemorrhagic shock: a controlled clinical trial. Surgery 89: 434–438, 1981

    PubMed  CAS  Google Scholar 

  • O’Donnell M. Battle of the clotbusters. British Medical Journal 302: 1259–1261, 25 May 1991

    Article  PubMed  Google Scholar 

  • Oh T, Franko TG. Implementing therapeutic interchange of intravenous famotidine for cimetidine and ranitidine. American Journal of Hospital Pharmacy 47: 1547–1551, 1990

    PubMed  CAS  Google Scholar 

  • Pharmaceutical Manufacturers Association. Biotechnology medicines in development. Pharmaceutical Manufacturers Association, Washington DC, 1990

    Google Scholar 

  • Powers T, Bingham DH. Clinical and economic effect of ciprofloxacin as an alternative to injectable antimicrobial therapy. American Journal of Hospital Pharmacy 47: 1781–1784, 1990

    PubMed  CAS  Google Scholar 

  • Rich DS. Experience with two-tiered therapeutic interchange policy. American Journal of Hospital Pharmacy 46: 1792–1798, 1989

    PubMed  CAS  Google Scholar 

  • Shires T, Colin D, Carrico J, Lightfoot S. Fluid therapy in hemorrhagic shock. Archive of Surgery 88: 688–693, 1964

    Article  CAS  Google Scholar 

  • Smith KS, Briceland LL, Nightingale CH, Quintiliani R. Formulary conversion of cefoxitin usage to cefotetan: experience at a large teaching hospital. DICP, Annals of Pharmacotherapy 23: 1024–1030, 1989

    CAS  Google Scholar 

  • Stumpf JL, Lechner JL, Ryan ML. Use of albumin in a university hospital: the value of targeted physician intervention. DICP, Annals of Pharmacotherapy 25: 239–243, 1991

    CAS  Google Scholar 

  • White HD, Rivers JT, Maslowski AH, Ormiston JA, Takayama M, et al. Effect of intravenous streptokinase as compared with that of tissue plasminogen activator on left ventricular function after first myocardial infarction. New England Journal of Medicine 320: 817–821, 1989

    Article  PubMed  CAS  Google Scholar 

  • Wolfman Jr EF, Neill SA, Heaps DK, Zuidema GD. Donor blood and isotonic salt solution. Archive of Surgery 86: 869–873, 1963

    Article  Google Scholar 

  • Wong YY, Abramowitz PA, Mansur JM. Changing use patterns of plasma volume expanders through educational intervention. American Journal of Hospital Pharmacy 44: 102–105, 1987

    PubMed  CAS  Google Scholar 

  • Wright DB. Antimicrobial formulary management: a case study in a teaching hospital. Pharmacotherapy 11 (Suppl. 1, part 2): S27–S31, 1991

    Google Scholar 

  • Zhanel GG, Gin AS, Przybylo A, Louie TJ, Otten NH. Effect of interventions on prescribing of antimicrobials for prophylaxis in obstetric and gynecologic surgery. American Journal of Hospital Pharmacy 46: 2493–2496, 1989

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. HPI Health Care Services, Department of Pharmaceutical Services, University Hospital, University of New Mexico Medical Center, 2211 Lomas Boulevard NE, Albuquerque, NM, 87106, USA

    Louis E. Achusim

Authors
  1. Louis E. Achusim
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Achusim, L.E. Therapeutic Interchange as a Cost-Containment Measure. PharmacoEconomics 2, 347–351 (1992). https://doi.org/10.2165/00019053-199202050-00001

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00019053-199202050-00001

Keywords

Search

Navigation